8-K filing — Yarrow Bioscience, Inc. (YARW)
Filed: 2026-09-14 AccNo: 0001104659-26-107485 Size: 582 KB Item 1.01: Entry into a Material Definitive Agreement Item 9.01: Financial Statements and Exhibits
Stocks · News reference
Yarrow Bioscience Q2 EPS $(2.14) Misses $(0.22) Estimate
Yarrow Bioscience (NASDAQ:YARW) reported quarterly losses of $(2.14) per share which missed the analyst consensus estimate of $(0.22) by 872.73 percent.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Reported Earlier, Yarrow Bioscience Prices $150M Underwritten Public Offering Of 5,769,231 Shares At $26.00 Per Share
Yarrow Bioscience Launches Underwritten Public Offering To Fund Pipeline Development And Corporate Operations; No Terms Disclosed
Yarrow Bioscience, Inc. ("Yarrow" or the "Company") (NASDAQ:YARW), a clinical-stage biotechnology company focused on developing transformative therapies for autoimmune thyroid diseases, today announced